Working within the principles of collaboration and transparency, each stakeholder can undertake actions to support the use of real-world evidence in Payer/HTA decisions about highly innovative technologies.
We invite organisations to participate in the public consultation on the Draft Stakeholder Actions, which will be open until the 28th of June 2024.
Click here to access the public consultation
See the Revision Timeline
Download the Paper Published in 2020
This paper goes beyond strategic intent to consider actions that regulators, HTA bodies, Payers, clinicians and patients could take to improve the use of real-world data to inform their decision. Case studies of recent Payer/HTA assessments about highly innovative technologies showed that there was a lack of clarity about the Payer/HTA questions that could be answered by RWD and how the quality of real-world evidence (RWE) could be assessed. For each stakeholder group, recommended actions to support the generation, analysis and interpretation of RWD to inform decision-making were developed.